甘李药业
(603087)
| 流通市值：412.70亿 | | | 总市值：442.05亿 |
| 流通股本：5.58亿 | | | 总股本：5.98亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,066,795,642.77 | 984,867,402.61 | 3,045,347,805.11 | 2,245,006,087.12 |
| 营业收入 | 2,066,795,642.77 | 984,867,402.61 | 3,045,347,805.11 | 2,245,006,087.12 |
| 二、营业总成本 | 1,515,608,273.35 | 739,374,819.17 | 2,663,266,844.19 | 1,921,772,067.24 |
| 营业成本 | 490,877,014.62 | 228,909,866.25 | 766,506,268.87 | 553,241,458.86 |
| 税金及附加 | 18,657,751.86 | 9,066,767.4 | 31,098,356.3 | 22,246,574.82 |
| 销售费用 | 656,481,754.37 | 326,526,305.76 | 1,167,041,098.71 | 831,334,688.22 |
| 管理费用 | 134,027,579.04 | 69,653,246.71 | 255,856,652.47 | 169,962,996.5 |
| 研发费用 | 264,523,560.46 | 130,445,929.06 | 541,045,258.13 | 403,442,931.89 |
| 财务费用 | -48,959,387 | -25,227,296.01 | -98,280,790.29 | -58,456,583.05 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 64,965,330.59 | 46,991,997.72 | 156,612,377.87 | 167,902,884.11 |
| 加:投资收益 | 7,078,197.36 | 3,388,058.82 | 61,249,137.11 | 55,851,319.43 |
| 资产处置收益 | - | - | 1,866,209.36 | 658,001.36 |
| 资产减值损失(新) | 18,215.12 | - | -15,656,632.99 | 16,817.47 |
| 信用减值损失(新) | -1,157,683.72 | -1,891,609.87 | 18,358,447.29 | 529,401.96 |
| 其他收益 | 9,513,575.34 | 5,061,170.15 | 27,029,652.52 | 14,065,608.78 |
| 四、营业利润 | 631,605,004.11 | 299,042,200.26 | 631,540,152.08 | 562,258,052.99 |
| 加:营业外收入 | 61,996,279.54 | 61,874,025.33 | 2,848,918.49 | 2,164,705.3 |
| 减:营业外支出 | 2,580,268.68 | 525,341.28 | 4,003,922.48 | 818,059.37 |
| 五、利润总额 | 691,021,014.97 | 360,390,884.31 | 630,385,148.09 | 563,604,698.92 |
| 减:所得税费用 | 87,340,442.49 | 48,472,161.29 | 15,721,347.39 | 56,339,499.4 |
| 六、净利润 | 603,680,572.48 | 311,918,723.02 | 614,663,800.7 | 507,265,199.52 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 603,680,572.48 | 311,918,723.02 | 614,663,800.7 | 507,265,199.52 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 603,680,572.48 | 311,918,723.02 | 614,663,846.87 | 507,265,245.69 |
| 少数股东损益 | - | - | -46.17 | -46.17 |
| 扣除非经常损益后的净利润 | 487,921,514.17 | 214,645,947.22 | 430,433,077.84 | 310,745,817.1 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.02 | 0.53 | 1.04 | 0.85 |
| (二)稀释每股收益 | 1.02 | 0.53 | 1.04 | 0.85 |
| 八、其他综合收益 | -21,049.12 | 338,986.22 | 219,526.81 | -865,256.02 |
| 归属于母公司股东的其他综合收益 | -21,049.12 | 338,986.22 | 219,526.81 | -865,256.02 |
| 九、综合收益总额 | 603,659,523.36 | 312,257,709.24 | 614,883,327.51 | 506,399,943.5 |
| 归属于母公司股东的综合收益总额 | 603,659,523.36 | 312,257,709.24 | 614,883,373.68 | 506,399,989.67 |
| 归属于少数股东的综合收益总额 | - | - | -46.17 | -46.17 |
| 公告日期 | 2025-08-08 | 2025-04-25 | 2025-04-25 | 2024-10-23 |
| 审计意见(境内) | | | 标准无保留意见 | |